Доктор Guy ERLICH

Доктор медицины

Израиль

Dr. Erlich Guy attained his general medicine degree from Charles University in Prague, Czech Republic, followed by an MSc. degree in aesthetic medicine and skin aging from the University of South Wales, UK. Currently he participates in his 2nd MSc. program in Clinical Dermatology at Buckingham University.

Dr. Erlich is the founder and CEO of G2 Aesthetics clinics in northern Israel. He also holds pivotal roles in the Aesthetics divisions at Mehuedet Health Organization and at Hillel Yafe Hospital's Plastic Surgery Unit.

Dr. Erlich serves as a Key Opinion Leader (KOL) for esteemed international aesthetic companies, and is a lecturer at international aesthetic conferences.

узнать больше

Guy ERLICH's графиков

IMCAS Asia 2025

июнь 7, 2025

Industry sponsored lectures

NOVOXEL - Tixel®: Precision meets performance in skin rejuvenation

июнь 8, 2025

Medical body shaping

Anatomical correlation in gluteal treatments: enhancing outcomes with injectables and energy-based devices

Contributed Talks - Regenerative medicine

From fibroblast activation to tissue remodeling: the science of skin renewal

CYNOSURE LUTRONIC Symposium - Powering modern aesthetics with Thulium & Q-Switched innovation

Adapting to skin diversity: Versatile and patient-centric approaches with the Hollywood spectra

Guy ERLICH's публикаций (2)

The Efficacy of Thermal Mechanical Fractional Injury System for Facial Rejuvenation: Subjective, Objective and Image Analysis Study.

Feb, 2025

Facial aging is the result of a number of factors, including the resorption of skeletal tissue, the atrophy of fat pads, and the laxity of connective tissue. These factors contribute to a reduction in facial volume and the development of skin changes. Thermal mechanical fractional injury (TMFI) represents a minimally invasive solution, stimulating collagen production and enhancing the delivery of topical formulations via epidermal microcraters. Подробнее

Journal of cosmetic dermatology

The role of tumor density in predicting significant cancer on targeted biopsy of the prostate.

Jul, 2023

Multiparametric magnetic resonance imaging (mpMRI) is central to diagnosing prostate cancer; however, not all imaged lesions represent clinically significant tumors. We aimed to evaluate the association between the relative tumor volume on mpMRI and clinically significant prostate cancer on biopsy. Подробнее

Urologic oncology